Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
Hyperphosphatemia
In-Center Nocturnal Hemodialysis May Improve HRQOL
In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.
SHPT, Hyperphosphatemia Independently Linked With CKD Progression
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Primary Failure of Arteriovenous Fistulas Linked to Elevated Phosphorus
Maintaining the patency of the AVF may be challenging in patients with hyperphosphatemia, study findings suggest.
Study IDs Most Effective Strategies to Reduce Fibroblast Growth Factor 23
Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.
Possible Optimal Parathyroid Hormone Range in Hemodialysis Cases Identified
Investigators found a U-shaped relationship between serum intact parathyroid hormone levels and death risk in Chinese patients initiating hemodialysis.
Tenapanor May Improve Phosphate Normalization in the Dialysis Population
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Nicotinamide May Improve Phosphate Control in Hemodialysis Patients
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.
Investigators ID Factors Affecting Predialysis Hemoglobin Control
Study findings reinforce the value of treating anemia during the transition to dialysis and illustrate the problem of ESA hyporesponsiveness.
- Loading...
Loading...
Next post in Anemia
Loading... 
Loading...